How many investments has Vivo Capital made?

Vivo Capital has 126 tracked investments, 27 of which have exited, including 3 dated in the last 24 months.

What stage does Vivo Capital invest at?

Vivo Capital invests at the Seed, Series A, Series B, Series C, Growth, Late Stage stages.

What is Vivo Capital's typical check size?

Vivo Capital typically writes checks of $10M – $50M.

What sectors does Vivo Capital focus on?

Vivo Capital focuses on Biotech, Digital Health, Healthtech, Medical Devices.

Where is Vivo Capital located?

Vivo Capital is headquartered in Palo Alto, US.

Does Vivo Capital lead rounds?

Yes, Vivo Capital leads investment rounds.

Who does Vivo Capital co-invest with?

Vivo Capital most often shares deals with RA Capital, venBio Partners, Samsara BioCapital, among 127 tracked co-investors.

Vivo Capital

Private equity

Palo Alto · Seed–Late Stage · 57 people tracked

Also known as VIVO CAPITAL LLC

★ Follow + Add to CRM ⤳ Find an introduction

Find your way into Vivo Capital

Each arrow is one introduction. Sign up to fill in the first one.

367 people can intro you to Michael

Ask Lisa Granick to introduce you to Michael Chang

You →Lisa · together at Fletcher Spaght, Inc. →Michael

317 people can intro you to Gaurav

Ask Jamie Chen to introduce you to Gaurav Aggarwal

You →Jamie · together at Investor Growth Capital →Gaurav

208 people can intro you to Jack

Ask Sam Okafor to introduce you to Jack Nielsen

You →Sam · together at Unchained Labs →Jack

Albert Cha169 people can intro you
Kevin Dai101 people can intro you
Frank Kung13 people can intro you

Your email: who you already know at Vivo Capital, and who your contacts know
2nd- and 3rd-degree connections: people you know who worked, studied or invested with the Vivo Capital team
Your LinkedIn: the connections who can make the intro for you

We rank every route by how warm it is, so you raise on warm intros instead of cold emails.

✨ Fox Verdict

Investment thesis

Vivo Capital is a global healthcare specialist deploying a multi-strategy investment platform across venture capital, private equity, and public equity. The firm targets the healthcare industry to broaden access to care and to catalyze innovation and growth, using what it calls an 'Ecosystem Strategy.' With over three decades in business, it has backed companies through numerous IPOs, M&As, and regulatory approvals across a broad global investment portfolio.

Invests inBiotech Digital Health Healthtech Medical Devices Asia-Pacific Brazil China Global Palo Alto United States

Source: firm website, verified Sep 29, 2026.

Leave your own feedback

Stage

Seed–Late Stage

Check

$10M – $50M

Palo Alto, CA, US

Leads rounds

Leads

Instruments

Equity

Founded

1996

Last 12 months

3 investments

AUM

$6.1B

Tracked investments

126

Unicorns

IPOs

Acquisitions

Team · 57 people

from the firm's website & public directories

Edgar G. Engleman· Managing Partner, Chief Scientific Advisor

Founding member and Chief Scientific Advisor of Vivo Capital, and a Stanford professor of pathology and medicine who established the Stanford Blood Center. Lead inventor of the Provenge cancer immunotherapy and cofounder of several biotech companies.

edengleman@vivocapital.com

Frank Kung· Managing Partner· Palo Alto, California

Founding partner of Vivo Capital and a biotech-industry veteran since 1979 who co-founded Cetus Immune and Genelabs Technologies, taking Genelabs public in 1991. Holds a chemistry B.S. from National Tsing Hua University and a Ph.D. in molecular biology plus M.B.A. from UC Berkeley.

fkung@vivocapital.com

Michael Chang· Managing Partner· Shanghaiin

Managing Partner with a healthcare strategy and operations background, having previously worked at Johnson & Johnson and as a strategy consultant at Booz & Company and Fletcher Spaght. Holds an economics degree from Harvard College and an M.B.A. from Harvard Business School.

mchang@vivocapital.com

Shan Fu· Managing Partner· Greater Chicago Areain

Managing Partner, Co-CEO, and CEO of Asia Pacific who joined Vivo in 2013 after serving as Senior Managing Director at Blackstone and chief of its Beijing office. Holds bachelor's and master's degrees in history from Peking University.

fushan@vivocapital.com

Gaurav Aggarwal· Managing Partner· Menlo Park, Californiain

Life sciences investor for over twenty years who rejoined Vivo as Managing Partner in 2024, having previously been Managing Director and CIO of the US public fund. Earned his M.D. from Columbia and a B.S. from Cornell.

Cinthia Sheu· Partner and COO

Partner and COO overseeing administration, finance, IT, and tax, with over 25 years in financial services and PE since 1999. Previously controller at Infinity Capital and a tax manager at PwC; a California CPA.

Zhanping Wu· Partner, General Counsel & Chief Compliance Officer

Partner, general counsel, and chief compliance officer overseeing legal, compliance, and regulatory programs. Previously corporate counsel at FibroGen and an attorney at Perkins Coie; holds a J.D. from UC Davis.

David Liu· Partner· Beijing

Partner with over 15 years of process R&D and CMC management experience in pharma, previously Executive Director of Process R&D at STA-WuXi AppTec. Holds a Ph.D. in Organic Chemistry from the University of Pittsburgh.

dliu@vivocapital.com

Jack Nielsen· Managing Partner· Palo Alto, Californiain

Jack Nielsen is a Managing Partner at Vivo Capital with over two decades of experience in life science venture capital investing. He focuses on therapeutics across all development stages and revenue-stage medical devices, with geographic emphasis on the US and EU markets.

jnielsen@vivocapital.com

Kevin Dai· Partner· San Francisco Bay Areain

Partner with healthcare and sell-side equity research experience who previously served as a clinical oncology pharmacy specialist at Memorial Sloan Kettering and an equity research associate at Canaccord Genuity. Board-certified oncology pharmacist with a Pharm.D. from Rutgers.

kdai@vivocapital.com

Albert Cha· Managing Partner· Palo Altoin

Chairman of the Board since 2021 and a director since 2014. A Managing Partner on Frazier's Life Sciences team with over 20 years of biopharmaceutical and medical device investing experience; previously a Managing Partner at Vivo Capital.

albert@frazierls.com

Andrew Huang· Principal

Principal responsible for growth and private equity investments who previously worked at Audax Private Equity and as an investment banker at J.P. Morgan. Holds a B.A. in Economics from UC Berkeley.

Chen Meng· Managing Director

Managing Director with over 20 years of private equity and healthcare investment experience, previously Managing Director at New Frontier Group and at a large Asian sovereign fund. Holds a Ph.D. in International Business from the University of Leeds.

Chole Zhang· Principal

Principal focused on sustainability initiatives who previously served as Director in the leveraged finance team at China Orient Asset Management International and worked at Bank of China Group Investment. Holds a B.B.A. in Finance and M.S. in Accounting.

Gilles Nkana· Principal

Principal who previously invested at Alta Semper Capital, a London-based healthcare private equity fund, and worked at Goldman Sachs in investment banking. Holds an M.B.A. from Columbia Business School.

Hao Dong· Managing Director

Managing Director with over 12 years of investment and entrepreneurship experience who previously worked at Qianhai Ark Asset Management and cofounded a NASDAQ-listed tech startup. Holds a B.S. in financial engineering from the University of International Business and Economics.

Jane Gong· Principal

Principal on the Investor Relations team who joined in 2021, working on fundraising, investor coverage, and reporting. Previously in IR at New Horizon/Redview Capital and an investment banking analyst at Houlihan Lokey.

Jiawei Liu· Principal

Principal with consulting and clinical experience who previously worked as a healthcare management consultant at Boston Consulting Group. Holds a medical degree from Shanghai Jiao Tong University.

Mike Lu· Principal

Principal with sell-side research and chemical biology research experience, previously a healthcare equity research analyst at Goldman Sachs. Holds a Ph.D. in Chemistry from MIT.

Pierre You· Principal, PIM

Principal on the PIM team with an audit and private markets background, previously at Deloitte, Fosun Group, and OFC Capital. Holds an M.B.A. from CEIBS.

Sean Zhang· Executive Director

Executive Director who previously was a Vice President at Lilly Asia Ventures focused on biotech venture capital and company incubation, and a consultant at McKinsey. Holds a Ph.D. in Molecular Biology from the University of Pittsburgh.

Timothy Stubbs· Executive Director

Executive Director who previously spent over seven years in Morgan Stanley's healthcare investment banking team in London and San Francisco. Earned his medical degree from the University of Bristol.

Nina Feng· Principal· Taipei

Principal in the Taipei office who joined Vivo in 2016, previously managing over USD 2 billion in private equity at Cathay Life Insurance. Holds a bachelor's and M.B.A. from National Cheng-Chi University and is a CFA.

nfeng@vivocapital.com

Zhongyi Lu· Executive Director· Shanghai

Executive Director with a private equity and investment banking background, previously at EQT and CITIC Xinjin. Holds a B.S. from Caltech, an M.S. from Johns Hopkins, and an M.B.A. from Wharton.

zlu@vivocapital.com

Priscilla Sugianto· Principal· United Statesin

Principal who previously worked at C-Bridge Capital as an Assistant Vice President across biopharma investment processes, including equity, licensing, royalty, and debt transactions. Holds an M.D. and M.B.A. from Stanford.

Xiaoyang li· Principal· Beijing

Principal with a multidisciplinary research background in medical sciences, nanotechnology, and chemistry. Holds a B.Eng. from Imperial College London and a Ph.D. in Chemistry from Stanford University.

Yixuan Li· Executive Director· Beijingin

Executive Director who joined Vivo in 2017 with a quantitative background, having previously been a public investment PE associate at Beijing Automotive Industry Holdings. Holds an M.S. from Oxford and a B.S. from University of Liverpool.

Dr. Shen· Venture Partner

Venture Partner who joined Vivo in 2016, an international pharmaceutical executive with over 40 years of experience and co-founder, President and CEO of ScinoPharm Taiwan. Holds a Ph.D. in Chemistry from Lehigh University.

Dr. Tsay· Venture Partner

Venture Partner who joined Vivo in 2016, a diagnostics-industry executive who was SVP and Group President of Thermo Fisher's Specialty Diagnostics business and founder of Diagnostics Reagents Inc. Holds a Ph.D. in Organic Chemistry from the University of Rochester.

Jo Shen· Venture Partner· Taiwanin

Yuh-geng Tsay· Venture Partner· Los Altos, California

Albert Chang· Executive Director, Head Trader

Head Trader who joined Vivo in 2017, bringing over 23 years of institutional asset management experience, with a focus on SMID cap biotech and pharma trading. Previously Head Trader at Palo Alto Investors and holds a B.A. from Harvard.

Allison Yan

Finance professional with a financial advisory and auditing background, previously at Ernst & Young with experience in IPO auditing and SOX compliance. US Certified Public Accountant with an M.A. in Accounting from North Carolina State University.

Brad· Associate, IR

Associate on the investor relations team supporting fundraising initiatives, previously at Horsley Bridge Partners and Eaton Partners' Private Funds Group. Holds a B.A. in Political Economy from NYU.

Christine Zhou· Analyst

Analyst on the Investor Relations team focused on client servicing and fundraising support, previously a research associate at J.P. Morgan's Asia Pacific Diversified Industries group. Holds an M.S. from Imperial College London and is an ACCA member.

Darren Long· Senior Associate, PIM

Senior Associate on the PIM team with a healthcare strategy consulting and business development background, previously with BeiGene and IQVIA Singapore. Holds a chemistry degree from NTU Singapore and an M.B.A. from INSEAD.

Jessica Li· Associate

Associate with a quantitative background whose prior experience includes CITIC Trust's asset management division and the US Department of Commerce. Holds a B.A. in Economics from NYU and an M.S. in Business Analytics from Duke.

Jing Wang· Senior Associate

Senior Associate who previously worked at Investcorp on its Greater China control buyout business and at a large Asian sovereign fund. Holds a master's in Finance from the University of Hong Kong.

Julie Zhang· Vice President of Tax

Vice President of Tax overseeing global tax compliance and transaction support with over 20 years in PE/VC tax, previously an M&A tax director at Deloitte China and tax manager at PwC US. Holds an M.S. in Accounting from Bentley University.

Kate Zhang· Senior Associate

Senior Associate with an investment banking background, previously at CEC Capital and Index Capital focused on healthcare service and technology. Holds an M.S. in Finance from Renmin University of China.

Linus Tan

Investment professional with fundamental and translational biomedical research experience, previously a senior associate at China Asset Management focused on biotech, vaccines, and CRO. Holds a Ph.D. in Chemical Biology from Tsinghua University.

Michael Chan· Analyst

Analyst with a biomedical engineering research and technology commercialization background who was a fellow at Columbia Technology Ventures. Earned his Ph.D. in Biomedical Engineering from Columbia University.

Mike Preigh

Pharmaceutical development and manufacturing expert with over 30 years of experience, most recently CTO at Day One Biopharmaceuticals and previously a CMC leader at Array BioPharma. Holds a Ph.D. in Chemistry from the University of Pittsburgh.

Qi Zhu· Head of Talent and Organization Development

Head of Talent and Organization Development overseeing HR and global talent strategy, who joined Vivo in 2013 as an investment professional before transitioning in 2020. Previously a consultant at McKinsey; holds degrees in Accounting from Fudan University.

Richard Ding· Analyst

Analyst who previously worked at Shine Asset Management on biopharmaceutical and computational biology investments. Holds a master's in financial engineering from Cornell and a computer science degree from CUHK.

Sophia Sun· Vice President, Head of China Operations

Vice President and Head of China Operations who joined Vivo in 2013, with over 25 years of operational management experience at multinational firms including Servier, Monitor Group, McKinsey, and Bayer.

Vera Yang· Senior Associate, IR

Senior Associate on the IR team with an advisory and auditing background, previously at Ernst & Young with SPAC audit and internal control experience. US Certified Public Accountant with an M.A. in Accounting from UIUC.

Vivian Chiau· Senior Vice President of Finance

Senior Vice President of Finance who joined Vivo in 2005 and oversees accounting operations and LP financial reporting, with over 20 years in venture capital including CDIB Venture Management. Holds a B.A. in Accounting from National Taiwan University.

Wenping Zhou· Associate

Associate with a biotech venture capital and sell-side equity research background, previously at Cantor Fitzgerald, Evercore ISI, and Connecticut Innovations. Holds a Ph.D. in Cell Biology from Yale University.

Zhao Wei

Investment professional with a private equity and investment banking background, previously at VMS Group and CDH Investments focused on healthcare. Holds an MBA from Columbia University.

Zoe Zhang

Investment professional with investment banking and R&D experience, previously at CEC Capital focused on biotech and pharmaceuticals. Holds a Ph.D. in Bioengineering from HKUST.

Chen Yu· Director

Daisy Xu· Managing Director· Shanghaiin

Commercial operations professional in the life science and medical equipment industries, previously Commercial Leader at ThermoFisher China and GM of Kinetic Concept Greater China. Holds an M.S. in Bio-engineering from East China University of Science and Technology.

dxu@vivocapital.com

Mahendra G. Shah· Advisor· San Francisco Bay Area

Pharmaceutical entrepreneur and former longtime Vivo Capital member (15+ years) who transitioned into an advisor role. Founder of Semnur Pharmaceuticals and former CEO of NextWave and First Horizon Pharmaceuticals; holds a Ph.D. from St. John's University.

mshah@vivocapital.com

Chen Bian· Associate· Shanghaiin

Daniel Qin· Associate· Palo Alto, California

Lingfei Zhao· Principal, PIM· Palo Alto, Californiain

Professional with a quantitative background who interned at BNP Paribas fixed income research and Blackstone Group as a PE analyst. Holds a B.S. from University of Wisconsin-Madison and an M.S. in Statistics from Cornell.

Founder mafia

2 people who came through Vivo Capital went on to found or lead other companies.

Joseph SilettoManaging PartnerFounded HistoWiz Mitchell MutzEntrepreneur PartnerFounded Amplyx Pharmaceuticals

What they invest in

from 105 of 126 portfolio companies

Biotech ×90Healthtech ×78Medical Devices ×37Deep Tech ×12Digital Health ×10Hardware ×10Advanced Manufacturing ×8Enterprise Software ×6

HQs:United States×72China×10Canada×2United Kingdom×2Singapore×2Taiwan×2

Who they back

founder profiles across 40 portfolio companies

48%

solo founders

19 of 40 mapped founding teams

33%

repeat founders

of 36 founders with career history

~4 yrs

old at investment

median across 13 dated deals

Founding team size:solo founder×192 founders×133 founders×34+ founders×5

Where their founders studiedfrom 36 founders with education data

Massachusetts Institute of Technology ×5University of California, Berkeley ×3Boston University ×2Caltech ×2Columbia University ×2Harvard Business School ×2Harvard University ×2Texas A&M University ×2

What their founders studiedfrom 34 founders with field-of-study data

Life Sciences ×14Engineering ×9Medicine ×6Chemistry ×5Physics ×5Economics ×3Business & Management ×2Computer Science ×2

Where their founders worked beforefrom 36 founders with career history

Bridgewater Associates ×2MAKO Surgical Corp. ×2Rigimmune ×2Stanford University ×2Vectura Group plc. ×2

26 founders hold a PhD · 5 hold an MBA (of 36 with degree data)

Investments · 126 tracked

founders shown can be your intro path

By year:2026 · 2 2025 · 1 2024 · 3 2023 · 2 2022 · 2 2021 · 9 2020 · 8 2019 · 4 2018 · 8 2017 · 4 2016 · 5 2015 · 355 dated

Crinetics Pharmaceuticalscrinetics.com in 𝕏NASDAQ: CRNXSeries B · Feb 2018 · $64M

Crinetics is a pharmaceutical company focused on discovering, developing, and commercializing therapies for endocrine diseases and endocrine-related conditions.

BiotechSan Diego, US

Richard Scott Struthers(Executive Officer, Director)Stephen F. Betz(Executive Officer)in Stephen Betz(Chief Scientific Officer)in R. Scott Struthers(President, Chief Executive Officer and Director)in Tobin Schilke(Chief Financial Officer)in Isabel Kalofonos(Chief Commercial Officer)in

Board seat Jack Nielsen· per SEC Form D

Co-investors5AM Ventures Foresite Capital OrbiMed RA Capital

Harmony Biosciencesharmonybiosciences.com in 𝕏NASDAQ: HRMYSep 2017

Harmony Biosciences develops innovative therapeutic treatments focused on rare neurological diseases.

BiotechHealthtechMedical DevicesNorthbrook, US

Jeffrey Aronin(Director)in Jeffrey M. Dayno, M.D.(President and Chief Executive Officer)inPatrick Morris(Secretary and Treasurer)inRobert Repella(Director and Chief Executive Officer)Darien Parhad(Chief Financial Officer)

Board Aaron Royston(Director)in

Board seat Jack Nielsen· per SEC Form D

Co-investorsAisling Capital HBM Healthcare Investments HBM Partners Paragon Biosciences LLC Pivotal Life Sciences Valor Equity Partners +3 more

Sera Prognosticsseraprognostics.com in 𝕏NASDAQ: SERAFeb 2021

Sera Prognostics develops women's health diagnostics focused on pregnancy, including the PreTRM blood test that predicts an individual's risk of spontaneous preterm birth in singleton pregnancies and the LikeMine platform that compares pregnancy outcomes using U.S. pregnancy data.

BiotechDigital HealthFemTechHealthtechSalt Lake City, US

Douglas Fisher(Executive Officer)Jay Moyes(Executive Officer)inGregory C. Critchfield(Executive Officer, Director)in Andrew A. Sauter(Executive Officer)inZhenya Lindgardt(President and Chief Executive Officer)in

BoardMansoor Mirza(Director)

Board seatJoseph Siletto· per SEC Form D

Co-investorsaMoon Excelestar Ventures OUP (Osage University Partners)UpStart Ventures Catalyst Health Ventures Domain Associates

Aadi Bioscienceaadibio.com inNASDAQ: WHWKMay 2018 · $23M

Aadi Bioscience develops therapies targeting mTOR-driven diseases using precision medicine and albumin-bound nanoparticle technology, applying genomic profiling to identify patients most likely to benefit from mTOR inhibition.

BiotechHealthtechMorristown, US

Scott Giacobello(Executive Officer)inBryan Ball(Executive Officer)Dave Lennon(Executive Officer, Director)inDavid Dornan(Executive Officer)James Murphy(Executive Officer)Stephen Pakola(Executive Officer)

Co-investors3B Future Health Fund Ally Bridge Group Decheng Capital Avoro Ventures OrbiMed

Achieve Life Sciencesachievelifesciences.com in 𝕏NASDAQ: ACHV

Achieve is a specialty pharmaceutical company developing and commercializing cytisinicline as a treatment for nicotine dependence, aimed at helping people who smoke quit.

BiotechHealthtechVancouver, B.C., US

Anthony Clarke(Executive Officer)Richard Stewart(Co-founder & Director (former President and CEO))Cindy Jacobs(Executive Officer, Director)in Jaime Xinos(Executive Officer)in John Bencich(Executive Officer, Director)inAndrew D. Goldberg(Chief Executive Officer & Director)in

Co-investorsLifeSci Venture Partners venBio Partners Frazier Life Sciences

Aclaris Therapeuticsaclaristx.comNASDAQ: ACRS

Aclaris develops investigational monoclonal antibodies and small-molecule inhibitors targeting immune pathways for the treatment of atopic, autoimmune, and respiratory diseases.

BiotechHealthtechMedical DevicesWayne, US

Neal Walker(Executive Officer, Director)Kamil Ali-Jackson(Executive Officer)Stuart D. Shanler(Executive Officer)inJoseph Monahan(Executive Officer)in Hugh Davis(Executive Officer, Director)inJames Loerop(Executive Officer)

Co-investorsAisling Capital APERTURE Venture Partners F-Prime Capital Foresite Capital RA Capital Sofinnova Ventures +1 more

Alto Neurosciencealtoneuroscience.com in 𝕏NYSE: ANRO

Alto Neuroscience is a clinical-stage biopharmaceutical company developing biology-driven medicines for neuropsychiatric conditions, using measurements of brain biology to predict clinical response and identify patients likely to benefit from its drug candidates.

BiotechDigital HealthMental HealthMountain View, US

Amit Etkin(Founder)inAdam Savitz(Executive Officer)inNicholas C. Smith(Executive Officer)inMichael Hanley(Executive Officer)Nicholas Smith(Chief Financial Officer and Chief Business Officer)inAaron Weaver(Director)

Co-investorsAble Partners Alpha Wave Global InVivium Capital K2 HealthVentures Korify Capital Nat Turner +6 more

Alx Oncologyalxoncology.com in 𝕏NASDAQ: ALXOSeries C · Feb 2020 · $110M

ALX Oncology develops therapies for cancer treatment, operating in the biotechnology and medical technology sectors.

BiotechHealthtechMedical Devices

Corey Goodman(Chairman)inJason Lettmann(Chief Executive Officer)in

Co-investorsLightstone Ventures age1 Foresite Capital HBM Healthcare Investments HBM Partners venBio Partners +1 more

Bolt Biotherapeuticsboltbio.com in 𝕏NASDAQ: BOLT

Bolt Biotherapeutics is a clinical-stage biotech company developing novel immunotherapies that leverage innate immune system mechanisms to treat cancer.

BiotechHealthtechMedical DevicesSan Francisco, US

Dr. Edgar G. Engleman(Founder)

Co-investorsPfizer Venture Investments Pivotal Life Sciences RA Capital Samsara BioCapital Sofinnova Ventures Nan Fung Life Sciences +3 more

Compass Pathwayscompasspathways.com in 𝕏NASDAQ: CMPS

Compass Pathways develops novel treatments for mental health conditions, with a focus on psychedelic-assisted therapies supported by rigorous clinical research.

BiotechDigital HealthHealthtechMedical DevicesMental Health

Kabir Nath(CEO)

Co-investorsAble Partners Aisling Capital Catalio Capital Management, LP Noetic OMX Ventures Jam Fund

Compass Therapeuticscompasstherapeutics.com in 𝕏NASDAQ: CMPXDec 2017

Compass Therapeutics uses proprietary antibody discovery platforms to generate and screen diverse panels of monoclonal and multispecific antibodies, aiming to identify synergistic therapeutic combinations.

BiotechHealthtechCambridge, US

Schuetz Thomas(Executive Officer, Director)in Errik Anderson(Executive Officer, Director)in Thomas J. Schuetz(Executive Officer, Director)inVered Bisker-Leib(Executive Officer)inBarry Shin(Chief Financial Officer)in Neil Lerner(Senior Vice President, Chief Accounting Officer)in

Co-investorsAlumni Ventures BioBrit F-Prime Capital Foresite Capital GV (Google Ventures)OrbiMed +3 more

Instil Bioinstilbio.com inNASDAQ: TIL

Instil Bio is a biotechnology company that identifies and acquires or licenses therapeutic candidates for development, with a strategic focus on securing additional novel drug candidates targeting diseases with significant unmet medical needs.

BiotechDallas, US

Bronson Crouch(Chief Executive Officer & Chairman of the Board)inSandeep "Steve" Laumas(Chief Financial Officer & Chief Business Officer)in Nimish Shah(Director)inGwen Binder(Director)Neil Gibson(Director)George Matcham(Director)

Co-investorsCurative Ventures CPMG Venrock

Mereo BioPharma Groupmereobiopharma.com inNASDAQ: MREOJun 2020

Mereo BioPharma is a biopharmaceutical company publicly traded on Nasdaq under the ticker MREO.

BiotechHealthtechLondon, GB

John Richard(Head of Corporate Development and Co-Founder)inCharles Sermon(General Counsel and Co-Founder)Richard Jones(Chief Financial Officer)inJill Henrich(Senior Vice President)inDenise Scots-Knight(Chief Executive Officer)in

BoardDr. Deepa Pakianathan(Non-Executive Director)

Co-investorsCancer Focus Pontifax Venture Capital Woodford Investment Management

Minerva Neurosciencesminervaneurosciences.comNASDAQ: NERV

Minerva Neurosciences is a clinical-stage biopharmaceutical company developing product candidates for central nervous system disorders.

BiotechHealthtechWaltham, US

Joseph Reilly(Executive Officer)Geoff Race(Executive Officer)inFred Ahlholm(Executive Officer)in Remy Luthringer(Executive Officer, Director)Mark Levine(Executive Officer)

Board Michele Ollier(Director)in

Co-investorsCare Capital Index Ventures Medicxi

Olema Pharmaceuticalsolema.com in 𝕏NASDAQ: OLMA

Olema is a clinical-stage biopharmaceutical company developing novel therapies for metastatic breast cancer and other endocrine-driven cancers, targeting nuclear receptors and mechanisms of acquired resistance.

BiotechHealthtechSan Francisco, US

Cyrus L. Harmon, Ph.D.(Director)Cyrus Harmon(Executive Officer, Director)in Cyrus L. Harmon(Director)inDavid C. Myles, Ph.D.(Executive Officer)Sean Bohen, M.D., Ph.D.(Executive Officer, Director)Naseem Zojwalla, M.D.(Executive Officer)in

Co-investorsAvoro Capital Advisors Bain Capital Life Sciences Foresite Capital Lightspeed Venture Partners RA Capital Biotechnology Value Fund +1 more

Pasithea Therapeuticspasithea.com in 𝕏NASDAQ: KTTA

Pasithea is a biotechnology company focused on the discovery and development of therapeutics for central nervous system disorders and RASopathies.

BiotechDeep TechHealthtechVenice, US

Lawrence Steinman(Director)Tiago Reis Marques(Chief Executive Officer)inIsrael Maxx Abramowitz(Executive Officer, Director)Craig Auringer(Executive Officer, Director)

Co-investorsJanus Henderson Investors

Passage Biopassagebio.com in 𝕏NASDAQ: PASGAug 2019 · $110M

Passage Bio is a biotechnology company developing treatments for central nervous system (CNS) diseases, with a focus on neurodegenerative conditions.

BiotechHealthtechPhiladelphia, US

William Chou(Chief Executive Officer)Tadataka Yamada(Executive Officer, Director, Promoter)Stephen Squinto(Executive Officer, Director)in

Board Patrick Heron(Director)in Carl Gordon(Director)inThomas Street Address 1 Woiwode(Director)

Co-investorsFrazier Life Sciences Access Biotechnology Frazier Healthcare Partners Lilly Asia Ventures New Leaf Venture Partners OrbiMed +2 more

Precision BioSciencesprecisionbiosciences.com in 𝕏NASDAQ: DTIL

Precision BioSciences develops gene-editing medicines using its proprietary ARCUS genome editing platform, which employs sequence-specific nuclease enzymes to insert, remove, or repair DNA in living cells to treat hard-to-treat conditions including rare genetic diseases and hepatitis B (HBV).

BiotechDeep TechHealthtechDurham, US

DEREK JANTZ(Executive Officer, Director)inMATTHEW KANE(Executive Officer, Director)Jeff Smith(Co-founder)in Derek Jantz(Co-founder)inTODD MELBY(Executive Officer)in Michael Amoroso(President, Chief Executive Officer)in

Co-investorsage1 Agent Capital Aliment Capital Brace Pharma F-Prime Capital OCV Partners +5 more

Silence Therapeuticssilence-therapeutics.comNASDAQ: SLNFeb 2021

Silence Therapeutics is a biotechnology company that discovers and develops short interfering RNA (siRNA) molecules designed to reduce the production of disease-associated proteins through the natural mechanism of RNA interference, with its proprietary mRNAi GOLD platform targeting specific genes in the liver for rare and common diseases.

BiotechLondon

Craig Tooman(Executive Officer)inGiles Campion(Executive Officer)Mark Rothera(Executive Officer, Director)inBarbara Ruskin(Executive Officer)

BoardJames Ede-Golightly(Director)Alistair Gray(Director)

Co-investorsForesite Capital MC Healthcare Ventures Nextech Invest

Sinovac Biotechsinovacbio.cnNASDAQ: SVA

Tarsus Pharmaceuticalstarsusrx.com in 𝕏NASDAQ: TARS

Tarsus is a biopharmaceutical company focused on developing and delivering medicines that target the root cause of serious diseases with high unmet need, including eye conditions.

BiotechHealthtechMedical Devices

Bobak Azamian, MD, PhD(Founder)in Bobak Azamian(President and Chief Executive Officer)inJeffrey Farrow(Chief Financial Officer and Chief Strategy Officer)Seshadri Neervannan(Chief Operating Officer)Aziz Mottiwala(Chief Commercial Officer)in Dianne Whitfield(Chief Human Resources Officer)in

Co-investorsAPERTURE Venture Partners Flying L Partners Frazier Life Sciences Visionary Ventures Bain Capital Life Sciences RTW Investments L.P.+1 more

Tenax Therapeuticstenaxthera.com inNASDAQ: TENX

Tenax Therapeutics is a clinical-stage pharmaceutical company developing TNX-103, an oral formulation of the drug levosimendan, to treat pulmonary hypertension resulting from heart failure with preserved ejection fraction (PH-HFpEF).

BiotechDigital HealthHealthtechChapel Hill, US

Stuart Rich(Chief Medical Officer)Lawrence R. Hoffman(Interim Chief Financial Officer)inMichael B. Jebsen(Executive Officer)Chris Giordano(President and Chief Executive Officer)inDoug Randall(Chief Business Officer)inTom Staab(Chief Financial Officer)in

Zai Labzailaboratory.com in 𝕏NASDAQ: ZLAB

Zai Lab is a global biopharmaceutical company developing and commercializing therapies in oncology, immunology, neuroscience, and infectious disease, with operations in China and the United States.

BiotechHealthtechMedical Devices

Samantha DuinSamantha (Ying) Du(Founder, Chief Executive Officer, Chairperson of the Board of Directors)in Yajing Chen(Chief Financial Officer)inRafael G. Amado(President, Head of Global Research and Development)in F. Ty Edmondson(Chief Legal Officer)inJosh Smiley(President and Chief Operating Officer)

Co-investorsQiming Venture Partners YuanBio Venture Capital Advantech Capital Kleiner Perkins Sequoia Capital

Zenas Biopharmazenasbio.com inNASDAQ: ZBIO

Zenas BioPharma is a biopharmaceutical company developing therapies for autoimmune diseases, with two late-stage drug candidates: obexelimab, a bifunctional monoclonal antibody targeting CD19 and FcγRIIb to suppress B cell activity, and orelabrutinib, an oral BTK inhibitor.

BiotechHealthtechWaltham, US

LEON O. MOULDER, JR.(Director)Lonnie Moulder(Founder, CEO & Chairman)JOSEPH FARMER(Executive Officer)HUA MU(Executive Officer, Director)in

Board PATRICK GERALD ENRIGHT(Director)inHONGBO LU(Director)

Co-investorsDelos Capital Longitude Capital New Enterprise Associates (NEA)Norwest Venture Partners Pivotal Life Sciences Quan Capital +2 more

Ascendis Pharmaascendispharma.com in 𝕏Nov 2014✓ verified

Ascendis Pharma is a biopharmaceutical company developing therapies for hormone-related disorders and rare diseases.

BiotechHealthtechMedical DevicesDenmark, DK

Jan Møller Mikkelsen(Founder, President and Chief Executive Officer)inGrethe Rasmussen(Executive Officer)inHarald Rau(Executive Officer)Martin Olin(Director)Lotte S?nderbjerg(Executive Officer)Martin Auster(Executive Officer)in

Co-investorsAisling Capital Avoro Capital Advisors Foresite Capital RA Capital Sofinnova Partners Sofinnova Ventures

Esco Lifesciences Groupescolifesciences.com in 𝕏May 2021 · $265M✓ verified

Esco Lifesciences manufactures laboratory equipment, biopharma devices, and IVF medical equipment for clinical, research, and industrial laboratories across more than 100 countries.

Advanced ManufacturingBiotechHardwareHealthtechMedical DevicesSingapore, SG

Lim Lay Yew(Founder)inLow Yae Foong(Founder)

Co-investorsGIC Novo Holdings

Fortis Therapeuticsfortistx.comSep 2016 · $18M✓ verified

Fortis Therapeutics develops therapeutic treatments based on technology licensed from UCSF, with a focus on oncology and other disease areas.

BiotechHealthtechMedical DevicesSan Diego, US

Marc Nasoff(Chief Scientific Officer)

Board Jay B. Lichter(Ph.D.)in

Co-investorsLilly Asia Ventures Osage University Partners Avalon BioVentures OUP (Osage University Partners)

Gracellbiogracellbio.com in✓ verified

Gracell Biotechnologies develops cell therapy manufacturing platforms and treatments, with a focus on CAR-T cell therapies for cancer and autoimmune diseases.

BiotechHealthtechMedical DevicesSuzhou, CN

William Wei Cao in

Co-investorsLAV Lilly Asia Ventures OrbiMed Pivotal Life Sciences Exome Asset Management Janus Henderson Investors +2 more

Inspirnainspirna.com in 𝕏Jul 2022 · $50M✓ verified

Inspirna is a clinical-stage biopharmaceutical company developing novel cancer drugs that target previously undruggable drivers of metastasis using its proprietary miRNA-DRIVEr platform.

BiotechHealthtechMedical DevicesNew York, US

Sohail Tavazoie(Co-Founder & Chair of Scientific Advisory Board)Masoud Tavazoie(Co-Founder & Advisor)in

Co-investorsSofinnova Partners Sands Capital Ventures Start Capital Novo Holdings

Neocisneocis.com in 𝕏✓ verified

Neocis develops Yomi, a robotic surgical platform that assists clinicians during dental implant surgery with planning, surgical, and restorative software features.

HealthtechMedical DevicesRoboticsMiami, US

Alon Mozes(CEO & Co-Founder)inJuan Salcedo(Engineering Fellow & Co-Founder)inJUAN SALCEDO(Executive Officer)inALON MOZES(Executive Officer, Director)inDennis Moses(Chief Technical Officer)inAndres Carrillo(VP of Product)in

Co-investorsIntuitive Ventures Norwest Venture Partners Mithril Capital Management B Capital Group DFJ Draper Fisher Jurvetson (DFJ)+2 more

Oricell Therapeuticsoricell.com in✓ verified

Oricell Therapeutics (原启生物) is a clinical-stage biopharmaceutical company developing cell therapies, including CAR-T products targeting GPRC5D for relapsed/refractory multiple myeloma and GPC3 for advanced liver cancer.

BiotechDeep TechHealthtechShanghai, CN

Helen Yang(Founder)in Iris Huang in

Co-investorsQiming Venture Partners Quan Capital RTW Investments L.P.

Abk Biomedical Incabkbiomedical.com in 𝕏Oct 2025SEC filingmedium confidence

ABK Biomedical is a clinical-stage medical device company that develops x-ray visible glass microspheres for Y-90 radioembolization and embolic treatment of cancers such as liver cancer.

BiotechHealthtechMedical DevicesHalifax, CA

Robert Abraham(Co-founder (Interventional Radiologist, MD))in Daniel Boyd(Co-founder (Material Scientist))in Sharon Kehoe(Co-founder (Material Scientist))in Anthony Headley(Executive Officer)in Gary Donofrio(Executive Officer)in Michael Mangano(Executive Officer, Director)in

Board seatJoseph Siletto· per SEC Form D · $2.6M raise · filed Nov 2025

Co-investorsEight Roads Ventures F-Prime Capital First Angel Network Association (FAN)

Aligos Therapeuticsaligos.com in 𝕏Dec 2019SEC filingmedium confidence

Aligos is a clinical-stage biotechnology company developing therapeutics for liver and viral diseases, including chronic hepatitis B virus (HBV) infection and MASLD/MASH.

BiotechHealthtechSouth San Francisco, US

Leonid Beigelman(President)inLawrence M. Blatt(Chairman, President & CEO (Co-founder))in Hardean Achneck(Executive Officer)in Brian Dowd(Executive Vice President - Controller)inLucinda Quan(Executive Vice President - General Counsel)in Julian Symons(Executive Vice President, Chief Scientific Officer)in

Board seat Jack Nielsen· per SEC Form D · $92.2M raise · filed Nov 2023

Co-investorsPivotal Life Sciences Roche Venture Fund MPM BioVentures 2014

AltheaDxaltheadx.comFeb 2018SEC filinghigh confidence

BiotechSan Diego, US

Francois Ferre(Director)Magda Marquet(Director)Jorge Garces(Executive Officer)inGreg Hamilton(Executive Officer, Director)Carin Sandvik(Executive Officer)Jeffrey G. Black(Executive Officer)

Board seatYuh-geng Tsay· per SEC Form D · $3M raise · filed Mar 2018

Co-investorsBioBrit Telegraph Hill Partners Ally Bridge Group WuXi Healthcare Ventures

Amyrisamyris.com inApr 2018 · $50M

Amyris develops a biomanufacturing platform that uses fermentation and microbial engineering to produce natural ingredients and rare compounds at scale for partners across industries such as specialty chemicals, food ingredients, and consumer products.

Advanced ManufacturingBiotechCleantechNew MaterialsEmeryville, US

NICHOLAS KHADDER(Senior Vice President, General Counsel & Secretary)RAFFI ASADORIAN(Chief Financial Officer)inJoel Cherry(President, Research & Development)inTamara Tompkins(Executive Vice President, General Counsel)inJohn Melo(President & Chief Executive Officer)in Paulo Diniz(Chief Financial Officer)in

Board seat Frank Kung· per SEC Form D

Co-investorsKleiner Perkins Maple Leaf Angels R7 Partners

Capniacapnia.com inMar 2015SEC filinghigh confidence

Capnia offers the CoSense ETCOc Monitor, a non-invasive breath test that measures end-tidal carbon monoxide to detect and quantify hemolysis and bilirubin production in newborns.

Digital HealthHardwareHealthtechMedical DevicesRedwood City, US

Anthony E. Burgos(Co-Founder and President of Bilitool, Inc.)Gina Phelps(Executive Officer)David D. O'Toole(Executive Officer)Anish Bhatnagar(Executive Officer, Director)Anthony Wondka(Executive Officer)

BoardSteinar Engelsen(Director)

Board seat Edgar G. Engleman· per SEC Form D · $3.7M raise · filed Mar 2015

Co-investorsAlliance VC Alliance Venture

Eiger BioPharmaceuticalseigerbio.comApr 2016SEC filinghigh confidence

BiotechSanta Clara, US

Jeffrey Glenn(Director)David Cory(Executive Officer, Director)

BoardNina Kjellson(Director)inEd Engleman(Director)

Board seat Edgar G. Engleman· per SEC Form D · $3M raise · filed Apr 2016

Co-investorsPfizer Venture Investments Canaan Partners

Mediaspacemediaspace.co in 𝕏Mar 2019SEC filingmedium confidence

Mediaspace is a digital agency that designs and builds custom Squarespace websites and provides SEO, digital marketing strategy, and digital advertising services.

AdTechAdvanced ManufacturingAI & Machine LearningData & InfrastructureDigital HealthEnterprise SoftwareHardwareHealthtechMarketing TechMedical DevicesSemiconductorsAtlanta, US

John G. Edwards(Executive Officer, Director)John Jacobi(Executive Officer)Sri Peruvemba(Executive Officer)Francois Jeanneau(Executive Officer, Director)Linda Ara(Executive Officer)Michael Vestel(Executive Officer)

Board seatNathan Dau Jack Nielsen· per SEC Form D · $22M raise · filed Dec 2021

Co-investors3E Bioventures Capital Keiretsu Forum Life Sciences Greenhouse Investments Toba Capital

ReadCoorreadcoor.com 𝕏Sep 2016 · $27M

Readcoor developed an in situ spatial transcriptomics platform using padlock probe rolling circle amplification chemistry to detect and map RNA transcripts across tissue sections, now offered as the Xenium In Situ platform.

BiotechDeep TechHardwareHealthtechCambridge, US

Evan Daugharthy(Cofounder)Richard Terry(Executive Officer, Director)

BoardVictor Tong(Director)Thomas Grogan(Director)

Board seatYuh-geng Tsay· per SEC Form D

Co-investorsDecheng Capital LAV Lilly Asia Ventures Lilly Ventures

Scientia Vascularscientiavascular.com inNov 2023 · $50M

Scientia Vascular develops guidewires, including the Aristotle and Zoom Wire product lines, for general vascular use within the neuro and peripheral vasculatures to introduce and position catheters and other interventional devices.

HealthtechMedical DevicesWest Valley City, US

John Lippert(Executive Officer, Director)Stacy Lippert(Executive Officer, Director)

BoardJeffrey Gladden(Dr. Gladden is a manager of the issuer.)David Bearss(Mr. Bearss is a manager of the issuer.)Rick Randall(Mr. Randall is a manager of the issuer.)Jerry Henley(Mr. Henley is a manager of the issuer.)

Board seatNathan DauJoseph Siletto· per SEC Form D

Co-investorsCowles Ventures

Swift Health Systems Inc.inAug 2021 · $102M

HealthtechIrvine, US

Kenny Chang(Executive Officer)W. Ronald Redmond(Director)Vijay Dhaka(Executive Officer)Philong Pham(Executive Officer, Director)Hongsheng Tong(Executive Officer, Director)

Board seatJoseph Siletto· per SEC Form D

Co-investorsBlackRock Endeavour Vision MVM Life Science Partners RTW Investments L.P.Soleus Capital venBio Global Strategic

35Pharma35pharma.com in

35Pharma is a biopharmaceutical company developing biologics to treat diseases with high unmet medical need.

BiotechHealthtech

Ilia(CEO)Maureen(CSO)

Co-investorsFrazier Life Sciences venBio Partners Janus Henderson Investors

ADARx Pharmaceuticalsadarx.com in

ADARx is a clinical-stage biotechnology company developing RNA-targeted therapeutics designed to control the expression of disease-driving genes.

BiotechHealthtechMedical DevicesSan Diego, US

Zhen Li(Co-founder, President & CEO)inRui Zhu(Founding Member & Chief Technology Officer)Rob Ackles(Chief People Officer)inRyan Fisk(Chief Financial Officer & Chief Business Officer)in Robert A. MacLeod(Chief Scientific Officer)in Christopher Claeboe(Senior Vice President of Operations)in

Co-investorsBain Capital Life Sciences OrbiMed SR One Capital Management Lilly Asia Ventures T. Rowe Price Ascenta Capital +3 more

Adaxion Therapeuticsadaxiontx.com in

ADAXION develops deimmunized biologic therapies using its ADAx platform, which incorporates proprietary CD22 ligands to eliminate therapeutic-specific B cells and reduce anti-drug antibody responses.

BiotechDeep Tech

Co-investorsJDRF T1D Fund

Adverum Biotechnologiesadverum.com 𝕏

Adverum is a clinical-stage gene therapy company developing Ixo-vec, an investigational single-administration intravitreal treatment for wet age-related macular degeneration and other ocular diseases, based on a proprietary adeno-associated virus (AAV) vector platform.

BiotechDeep TechHealthtechRedwood City, US

Thomas W. Chalberg(Executive Officer, Director)Steven D. Schwartz(Director)Mark S. Blumenkranz(Director)Linda Rubinstein(Executive Officer)Setareh Seyedkazemi(Executive Officer)Kishor Peter Soparkar(Executive Officer)

Co-investorsAvoro Capital Advisors Frazier Life Sciences 5AM Ventures Samsara BioCapital Venrock Healthcare Capital Partners

Aerobiotixaerobiotix.com in 𝕏May 2021 · $25M

A medical device company developing orthopedic and biological solutions.

BiotechCleantechHardwareHealthtechMedical DevicesOhio, US

David Kirschman(Surgeon Inventor)in

Co-investorsAsahi Kasei Corporate Venture Capital Horizon Technology Finance

Agno Pharmaagnopharma.com in

Agno Pharmaceuticals is a US-headquartered contract development and manufacturing organization (CDMO) that produces regulatory starting materials, intermediates, active pharmaceutical ingredients, and drug formulations for pharmaceutical and biotech companies.

Advanced ManufacturingBiotechHealthtechUnknown (US-headquartered stated, but specific city not provided), US

Ajax Therapeutics Inc.ajaxtherapeutics.comAcquired

Ajax Therapeutics is a biotech company developing Type II JAK2 inhibitors for the treatment of myeloproliferative neoplasms (MPNs), including myelofibrosis, using computational chemistry and structural biology in its drug discovery.

AI & Machine LearningBiotechHealthtechNew York, US

Martin Vogelbaum(CEO, co-founder)inRoss Levine(Director)Ramy Farid(Director)

BoardScott Platshon(Director)

Co-investorsInning One Ventures EcoR1 Capital RA Capital Revelation Partners

AkiraBioakirabio.com in

Akira Bio develops therapies for people living with sickle cell disease and other hemoglobinopathies.

BiotechHealthtech

Anokionanokion.comSeries A · May 2014 · $38M

Co-investorsVersant Ventures MPM BioImpact

Attralusattralus.com in 𝕏Feb 2024 · $56M

Attralus develops pan-amyloid removal (PAR) therapeutics — biologics and imaging agents designed to bind and remove toxic amyloid — to treat patients with systemic amyloidosis across all disease types and stages.

BiotechHealthtechSouth San Francisco, US

Jonathan Wall(Executive Officer)inSpencer Guthrie(Executive Officer)Mark Timney(Executive Officer, Director)inBenson Fong(Executive Officer)Rahul Kakkar(Director)inGreg Bell(Executive Officer)

Co-investorsAlpha Wave Global BioBrit LifeSci Venture Partners venBio Partners Janus Henderson Investors REDMILE +2 more

Bhtherapeuticsbhtherapeutics.com

BH Therapeutics is a drug development company that uses structure-based rational drug design to identify structural limitations in existing therapies and design novel chemical scaffolds to address them.

Biotech

J. Jean Cui, Ph.D.(Scientific Founder, President and CEO)Y. Peter Li, Ph.D., MBA(Cofounder and Executive Chairman)

Co-investorsOrbiMed

BioDlinkbiodlink.com

BioDlink is a contract development and manufacturing organization (CDMO) providing drug development and manufacturing services for biopharmaceutical companies, with specialization in antibody-drug conjugates (ADCs).

Advanced ManufacturingBiotechEnterprise SoftwareHealthtechSuzhou, CN

Bonraybiobonraybio.com in

Bonray Bio develops miniaturized microscopy optics and AI-powered image analysis software for reproductive medicine diagnostics, providing male infertility diagnostic instruments and consumables to fertility clinics globally.

AI & Machine LearningBiotechFemTechHealthtechMedical DevicesTaiwan, TW

Bonum Therapeuticsbonumtx.com in 𝕏

Bonum Therapeutics develops antibody-controlled protein therapeutics that remain inactive until bound to their target, using a sensor-domain mechanism to deliver regulated, targeted activity.

BiotechHealthtechSeattle, US

John Mulligan(Executive Officer, Director, Promoter)in Neela Patel(Executive Officer)inDiane Hollenbaugh(Executive Officer)in

Board Samuel Bjork(Director)in Monique Schiersing(Director)in John McKearn(Director)in

Co-investorsRiverVest Venture Partners Roche Venture Fund 3x5 Partners Codon Capital Digitalis Ventures

Caidyacaidya.com in

Caidya provides clinical trial management solutions designed for pharmaceutical and biotech companies seeking to improve trial efficiency and patient outcomes through integrated, patient-centric approaches.

BiotechDigital HealthHealthtech

Barbara Lopez Kunz(Chief Executive Officer)in Michael Clay(Chief Operating Officer)inSharon Moore(Chief Medical Officer)in Brandon Pallott(Chief Commercial Officer)in Miron Lila(Chief Corporate Development Officer)in John Scott(Chief Information Officer)in

Co-investorsQiming Venture Partners Hatteras Venture Partners

Cidara Therapeuticscidara.com in 𝕏

Pharmaceutical company developing medicines and vaccines for patient health and treatment.

BiotechHealthtechSan Diego, US

Jeffrey Stein(Executive Officer, Director)Kevin Judice(Director)inKevin Forrest(Executive Officer)Dirk Thye(Executive Officer)inKen Bartizal(Executive Officer)in Paul Daruwala(Executive Officer)in

Co-investors5AM Ventures Aisling Capital Bain Capital Life Sciences Frazier Life Sciences RA Capital Canaan Partners +1 more

Clasp Therapeuticsclasptx.com inSeries A · Mar 2024 · $150M

Clasp Therapeutics develops off-the-shelf precision T cell engagers (its proprietary pHLАre molecules) that target mutant peptide-HLA complexes displayed on cancer cells, directing T cells to destroy tumors carrying common driver mutations such as KRas.

BiotechHealthtechCambridge, US

Co-investorsCatalio Capital Management, LP Cure Ventures Catalio Capital Management Novo Holdings Third Rock Ventures

Creaternacreaterna.com

Lang Lai Technology (朗来科技) is a clinical-stage drug discovery company that runs an end-to-end new-drug R&D process spanning proof of concept, candidate compound screening, preclinical druggability development, and clinical research, pursuing both pipeline development and platform building.

BiotechHealthtechWuhan, CN

Co-investorsOrbiMed Lilly Asia Ventures

Dominique Dutscherdutscher.com in

Dutscher provides after-sales service (SAV) and post-delivery support (SAL) for laboratory equipment and consumables, handling warranty claims, non-warranty repairs, maintenance, product returns, and transport damage resolution.

Advanced ManufacturingB2B MarketplacesBiotechDeep TechE-commerceEnterprise SoftwareSaaS

Other

Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.

Bolt TherapeuticsPreventice Solutions, Inc.REATA PHARMACEUTICALS INCAvadel PharmaceuticalsAvistone PharmaceuticalsCaldera Therapeutics, Inc.Cerebral TherapeuticsGenetronIVERIC BioLepu Scientech Medical TechnologyManaT Bio Menlo TherapeuticsNew Frontier CorporationNexcida Therapeutics Ocelot BioRareStone GroupRevance TherapeuticsRiboX TherapeuticsSinovac Life & SciencesSuzhou Omini PharmaeuticalTranquis TherapeuticsVisirna Therapeutics

Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.

Exits · 27

26 IPOs · 1 acquisitions · showing 24

Crinetics PharmaceuticalsNASDAQ: CRNXHarmony BiosciencesNASDAQ: HRMYSera PrognosticsNASDAQ: SERAAadi BioscienceNASDAQ: WHWKAchieve Life SciencesNASDAQ: ACHVAclaris TherapeuticsNASDAQ: ACRSAlto NeuroscienceNYSE: ANROAlx OncologyNASDAQ: ALXOBolt BiotherapeuticsNASDAQ: BOLTCompass PathwaysNASDAQ: CMPSCompass TherapeuticsNASDAQ: CMPXInstil BioNASDAQ: TILMereo BioPharma GroupNASDAQ: MREOMinerva NeurosciencesNASDAQ: NERVOlema PharmaceuticalsNASDAQ: OLMAPasithea TherapeuticsNASDAQ: KTTAPassage BioNASDAQ: PASGPrecision BioSciencesNASDAQ: DTILSilence TherapeuticsNASDAQ: SLNSinovac BiotechNASDAQ: SVATarsus PharmaceuticalsNASDAQ: TARSTenax TherapeuticsNASDAQ: TENXZai LabNASDAQ: ZLABZenas BiopharmaNASDAQ: ZBIO

Portfolio news

latest coverage across their companies

Silence Therapeutics to Participate in Three September 2026 Investor Conferences - BioSpace

Silence Therapeutics · biospace.com · Sep 2, 2026

Precision BioSciences Reports Second Quarter 2026 Financial Results and Provides Business Update - BioSpace

Precision BioSciences · biospace.com · Aug 6, 2026

SonoThera Raises $125M in Series B Funding

SonoThera · finsmes.com · Jun 10, 2026

Compass Therapeutics to Participate in Upcoming June 2026 Investor Events - BioSpace

Compass Therapeutics · biospace.com · May 28, 2026

Achieve Life Sciences Announces Up to $354 Million Private Placement

Achieve Life Sciences · finance.yahoo.com · Apr 16, 2026

Oricell Therapeutics Closes $110M Pre-IPO Financing

Oricell Therapeutics · finsmes.com · Apr 10, 2026

35Pharma to be Acquired by GSK to Accelerate Development of HS235, a Potential Best-in-Class Investigational Medicine for Pulmonary Hypertension (PH)

35Pharma · finance.yahoo.com · Feb 25, 2026

Pasithea Therapeutics Provides Outlook on PAS-004 Clinical Programs and Data Release Timelines - BioSpace

Pasithea Therapeutics · biospace.com · Jan 13, 2026

Fund performance · per public LP disclosures · 4

as of Jun 2025

Fund	Vintage	Committed	Net IRR	TVPI	DPI
Vivo Capital IXLPs: California State Teachers' Retirement System, Baltimore City Employees' Retirement System	2019	—	18.8%	1.73x	0.70x
Vivo Opportunity Fund, LPLPs: Empire State Development – New York Ventures	2018	—	—	1.84x	1.84x
Vivo Capital Fund VIII, L.P.LPs: California State Teachers' Retirement System	2015	—	14.9%	1.96x	1.51x
Vivo Capital Surplus Fund VIII, L.P.LPs: California State Teachers' Retirement System	2015	—	15.9%	2.01x	1.55x

Source: public limited-partner disclosures (CalPERS, CalSTRS). Net IRR / TVPI / DPI as reported by the limited partner; a fund's early-year IRR is an interim estimate (J-curve).

IPO stake values · per SEC filings · 7

Value of this firm's stake in each portfolio company at its IPO price, from the prospectus principal-stockholder table.

Company	Owned	IPO price	At IPO	Stake value
Alx Oncology	10.7%	$76.00	Dec 2020	$320.7M
Instil Bio	9.6%	$20.00	Mar 2021	$243.7M
Harmony Biosciences	8.0%	$24.00	Aug 2020	$121.5M
Bolt Biotherapeutics	11.2%	$20.00	Feb 2021	$77.4M
Tarsus Pharmaceuticals	15.4%	$16.00	Oct 2020	$47.9M
Passage Bio	5.1%	$18.00	Feb 2020	$40.1M
Sera Prognostics	5.3%	$16.00	Jul 2021	$25.7M

Source: SEC S-1 / 424B prospectus filings. Stake value = shares beneficially owned × the initial public offering price, as disclosed — a market value at IPO, not a return multiple (the firm's original cost is not disclosed).

Public market activity · per SEC filings

what is this? ⓘ

14 insider ownership filings (Forms 3/4/5)

From the firm's own SEC EDGAR filings — stakes and insider roles in public companies, typically portfolio companies after an IPO. Not a portfolio list published by the firm.

Frequently asked questions

How many investments has Vivo Capital made?: Vivo Capital has 126 tracked investments, 27 of which have exited, including 3 dated in the last 24 months.
What stage does Vivo Capital invest at?: Vivo Capital invests at the Seed, Series A, Series B, Series C, Growth, Late Stage stages.
What is Vivo Capital's typical check size?: Vivo Capital typically writes checks of $10M – $50M.
What sectors does Vivo Capital focus on?: Vivo Capital focuses on Biotech, Digital Health, Healthtech, Medical Devices.
Where is Vivo Capital located?: Vivo Capital is headquartered in Palo Alto, US.
Does Vivo Capital lead rounds?: Yes, Vivo Capital leads investment rounds.
Who does Vivo Capital co-invest with?: Vivo Capital most often shares deals with RA Capital, venBio Partners, Samsara BioCapital, among 127 tracked co-investors.

Co-investors · 24

RA Capital

RA Capital Management is a healthcare and planetary health investment firm that founds, funds, and scales companies using scientific diligence, multi-stage capital, and hands-on operational support.

Both backed · 18

Aclaris Therapeutics Bolt Biotherapeutics Crinetics Pharmaceuticals Olema Pharmaceuticals Precision BioSciences Ajax Therapeutics Inc.Ascendis Pharma Cerebral Therapeutics Cidara Therapeutics Gracellbio IO Biotech Kinaset Therapeutics Ocelot Bio Regulus Satsuma Pharmaceuticals Serapha Bio Sierra Oncology SonoThera

venBio Partners

venBio is a life sciences venture capital firm that partners with industry leaders to develop novel therapeutics and technologies addressing unmet medical needs.

Both backed · 14

Achieve Life Sciences Alx Oncology Compass Therapeutics Harmony Biosciences Precision BioSciences 35Pharma Attralus Caldera Therapeutics, Inc.HistoWiz Menlo Therapeutics Metacrine Neurogastrx Rayze Bio Verona Pharma

OrbiMed

OrbiMed is a healthcare-focused investment firm providing tailored financing solutions and global resources to build world-class healthcare companies across biopharmaceuticals, medical devices, digital health, diagnostics, and healthcare services.

Both backed · 10

Aadi Bioscience Compass Therapeutics Crinetics Pharmaceuticals Passage Bio ADARx Pharmaceuticals Bhtherapeutics Createrna Gracellbio Neurogastrx Zai

$1M – $75M

Aisling Capital

Aisling Capital is an investment firm focused on companies developing and commercializing innovative healthcare products, services, and technologies.

Both backed · 10

Aclaris Therapeutics Harmony BiosciencesCompass PathwaysAscendis Pharma Cidara Therapeutics MEI Pharma Menlo Therapeutics Poseida Therapeutics Tria Beauty Verona Pharma

Lilly Asia Ventures

Lilly Asia Ventures (LAV) is a biomedical venture capital firm with offices in Hong Kong, Shanghai, and Palo Alto, backing entrepreneurs building companies focused on breakthrough products that treat disease and improve human health.

Both backed · 10

Passage Bio ADARx Pharmaceuticals Createrna Fortis Therapeutics Gracellbio Metacrine ReadCoor Rgenta Therapeutics Ronovo Surgical Terns Pharmaceuticals

F-Prime Capital

F-Prime Capital is an early-stage-focused investment firm backing companies across life sciences, technology, healthtech and services, and crypto.

Both backed · 6

Aclaris Therapeutics Compass Therapeutics Precision BioSciences Abk Biomedical Inc Menlo Therapeutics Pulmocide

$3M – $10M

Qiming Venture Partners

Qiming Venture Partners (启明创投) is a China-focused venture capital firm that invests in and supports early- and growth-stage technology and healthcare companies, providing capital, industry resources, and strategic guidance through milestones such as financing, IPOs, and M&A.

Both backed · 5

Zai Lab Caidya Oricell Therapeutics Sanegene BioRiboX Therapeutics

$5M – $134M

Versant Ventures

Versant Ventures operates in-house Discovery Engines staffed by multidisciplinary scientists in dedicated laboratory facilities to help launch new biotechnology companies alongside academic founders.

Both backed · 3

Passage Bio Rayze BioAnokion

$250K – $5M

Deerfield Management Company

Deerfield Management is a healthcare-focused investment firm that supports companies across the healthcare ecosystem through flexible funding, market intelligence, and philanthropic initiatives.

Both backed · 3

Homology Medicines Metacrine SentreHeart

Third Rock Ventures

Third Rock Ventures is a venture capital firm that discovers, launches, and builds life sciences and biotechnology companies developing novel medicines and therapies.

Both backed · 3

Clasp Therapeutics ManaT Bio Platelet BioGenesis

$100K – $5M

GV (Google Ventures)

GV (Google Ventures) is a venture capital firm that has invested in AI and machine learning since its early days, backing more than 100 AI companies across infrastructure, life sciences, and applications.

Both backed · 2

Compass Therapeutics Epi Biologics

$250K – $50M

Polaris Partners

Polaris Partners is a venture capital firm that partners with biotech and healthcare entrepreneurs to build transformational companies.

Both backed · 2

Epi Biologics Metacrine

$500K – $5M

▶12 more co-investors

Atlas Venture MPM BioImpact Domain Associates Digitalis Ventures Vida Ventures aMoon Toba Capital Catalio Capital Management Catalio Capital Management, LP Kurma Partners Earlybird Venture Capital CincyTech

Firms observed investing alongside Vivo Capital, from public investor directories. Shared companies are the overlap with Vivo Capital's recorded portfolio.

Similar investors

Eight Roads Ventures

Eight Roads Ventures is a venture capital firm that backs and partners with technology and healthcare companies.

$5M – $30M

Khosla Ventures

Khosla Ventures is a venture capital firm that backs bold, early-stage, technology-driven companies across deep tech and other sectors, providing hands-on 'venture assistance' to help founders build category-defining businesses.

$5K – $50M

Sofinnova Ventures

Sofinnova is an investment firm focused on the life sciences and biotechnology sector, partnering with companies from inception through drug development, regulatory approval, company building, and IPO.

$100K – $15M

RiverVest Venture Partners

RiverVest Venture Partners is a life sciences venture capital firm that invests in biotechnology and medical companies, working with entrepreneurs to advance therapeutic and medical innovations.

$500K – $3M

Pitango

Pitango is an Israel-based venture capital firm that has backed founders across technology sectors for decades, offering portfolio companies access to a broad network of customers, partners, and leaders.

$4M – $100M